Summary of COVID-19 ixekizumab studies

1. Pimenta Bonifácio et al., Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)

32 patient ixekizumab late treatment RCT: 50% higher mortality (p=1) and no change in improvement (p=1).
Open label RCT late stage hospitalized patients in Brazil showing no significant difference with IL-2 or ixekizumab treatment. Mortality was lower and recovery was greater with colchicine, without statistical significance.
Apr 2022, Revista da Sociedade Brasileira de Medicina Tropical, http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822023000100317&tlng=en, https://c19p.org/pimentabonifacio2ixe